https://www.selleckchem.com/pr....oducts/Mizoribine.ht
l manifestations. In their 2018 article, Lezcano et al [AJSP 2018(11)1456] show that diffuse tumor cell nuclear reactivity for Preferentially expressed Antigen in Melanoma (PRAME) is a feature of melanoma and that benign and atypical melanocytic tumors are PRAME negative or show only focal positivity for PRAME. We report our observations of PRAME staining in 253 melanocytic tumors. Tumors were classified by hematoxylin and eosin sections. The nuclear PRAME staining of neoplastic melanocytes in each case was categorized as absent, foc
Like
Comment
Share
